SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 5, 2002
AVI BioPharma, Inc.
(Exact name of registrant as specified in its charter)
| Oregon | 0-22613 | 93-0797222 | ||
| (State or other jurisdiction of incorporation or organization) |
(Commission File Number) | (IRS Employer Identification Number) |
One S.W. Columbia, Suite 1105
Portland, OR 97258
(Address of principal executive offices)
(503) 227-0554
Registrant's telephone number, including area code
AVI BioPharma, Inc. (the "Company") issued a press release on November 5, 2002, before the opening of trading in its Common Stock on the Nasdaq National Market System, a copy of which is attached as Exhibit 99.
The Press Release announces Third Quarter Financial Results and updates the Company's product research and clinical trials.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
None
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Portland, State of Oregon, on November 5, 2002.
| AVI BioPharma, Inc. | |||
By: |
/s/ ALAN P.TIMMINS Alan P. Timmins President and Chief Operating Officer (Principal Operating Officer) |
||
2